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L E T T E R  T O  T H E  E D I T O R
Response to "prognostic biomarkers in oral leukoplakia"
Dear Editor,
We thank Professor Warnakulasuriya for his letter 
(Warnakulasuriya, 2019) and comments in relation to our systematic 
review of prospective studies assessing the prognostic biomarkers of 
oral leukoplakia (Villa, Celentano, et al., 2019). We agree that identify-
ing prognostic biomarkers for oral leukoplakia is an important topic for 
oral medicine specialists. Hence our commitment is to address such a 
diverse and scientifically challenging area as a component of World 
Workshop of Oral Medicine VII.
We would like to clarify, though, that this first paper in a series 
of papers on the topic examined prognostic biomarkers for oral 
leukoplakia in context of biomarker expression in human subject 
samples. Details of the search strategy, including potentially eligible 
studies, search terms, and strategy are detailed in our paper (Villa, 
Celentano, et al., 2019).
In relation to the putative biomarkers identified by Professor 
Warnakulasuriya, we would agree that many of these have been 
highlighted in the literature, some being more prognostic than 
others.
• However, several studies that discuss these biomarkers did not 
meet the inclusion criteria for our systematic review. For exam-
ple, many studies did not specifically detail the oral leukoplakia 
cases, and this hampered inclusion of many papers and potential 
biomarkers, not only those raised by Professor Warnakulasuriya, 
but also some described by authors of the current systematic 
review.
• Additionally, as we reported in point “c)” of paragraph “2.1”, we did 
not include any review papers or those discussing meta‐analyses, 
such as the publication by (Alaizari, Sperandio, Odell, Peruzzo, 
& Al‐Maweri, 2018). We only considered original studies for in-
clusion and exclusion reviews or collective analyses of multiple 
studies. Detailed information of biomarkers identified, including 
prognostic information (when mentioned in the papers), are re-
ported in the Supplementary data.
A recurrent confounder for the development of our manuscript 
was imprecise description of the anatomical location of the lesions. 
As an example, several cases of not otherwise specified “oropha-
ryngeal leukoplakias” could not be included for our analysis. In 
addition, many studies on putative biomarkers for oral leukopla-
kia actually describe them in terms of presence or absence of oral 
epithelial dysplasia without clear clinical information to warrant 
inclusion. As shown in Table 1 of our paper (Villa, Celentano, et al., 
2019), exclusion category N3 captured 332 studies out of a total of 
418 reports ineligible for inclusion due to lack of definitive clinical 
diagnosis and presentation of dysplasia data only.
We agree that the definition of oral leukoplakia in some studies 
may have affected the papers selected. However, this in an inher-
ent limitation with the papers themselves, and the broader field 
of oral medicine, and not restricted to the inclusion criteria of our 
systemic review. We acknowledge that authors of some publica-
tions have included keratotic white lesions as potential leukoplakia, 
which complicates analysis of potential biomarkers for the latter 
condition. This issue is highlighted in a recent study by Villa, Hanna, 
et al. (2019) which touches on the molecular profile of non‐dys-
plastic leukoplakic lesions commonly reported histopathologically 
as benign keratosis in the literature, but identified as leukoplakia 
clinically. Unfortunately, without access to all details of studied 
cases, it is not possible to determine which cases could be validated 
for inclusion.
Rationale for study exclusion was clearly articulated in our 
paper. Although we agree that a table summarizing rationale could 
have been helpful, the sheer number of studies excluded precluded 
this from a practical point of view. We included an Appendix to this 
letter with all the excluded studies for clarity (Appendix 1). Finally, 
we agree with Professor Warnakulasuriya that few, if any, of the 
prognostic biomarkers reported in the literature for oral leukopla-
kia are robust. Although some may hold more promises than oth-
ers, including some omitted from our report, we could only report 
on those that met the inclusion criteria of the current systematic 
review.
Addressing the following issues in future studies (as we specified 
in Section 4.1 “Future directions” in the manuscript) would further 
strengthen the quality and clinical value of this line of research:
• Both clinical and histopathological details should be provided to 
allow analysis of clinical entities such as leukoplakia and corre-
sponding histopathological entities such as dysplasia, in terms of 
identification of putative biomarkers. A recent paper by Farah and 
Fox (Farah & Fox, 2019) discusses this philosophical question by 
identifying the molecular profile of oral leukoplakia with and with-
out dysplasia.
• A more concerted effort is required internationally to correctly 
define oral leukoplakia, as the current definition is not entirely 
helpful in a clinical sense.
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Respectfully,
Alessandro Villa, Antonio Celentano, Ingrid Glurich, Wenche S. 
Borgnakke, Siri Beier Jensen, Douglas E. Peterson, Konstantina Delli, 
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